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A new colchicinoid from Colchicum crocifolium Boiss. (Colchicaceae) was isolated and 
identified as N,N-dimethyl-N-deacetyl-(−)-cornigerine (5), along with four known compounds, 
but new to the species: (−)-colchicine (1), (−)-demecolcine (2), (−)-N-methyl-(−)-demecolcine 
(3) and 3-demethyl-N-methyl-(−)-demecolcine (4). All isolated compounds showed potent 
cytotoxicity against a human cancer cell panel. 
 






As part of our studies on the unique and under explored biodiversity of the Hashemite Kingdom 
of Jordan (Jordan) (Alali et al., 2005, 2006a, 2006b; Alali, Gharaibeh, Ghawanmeh, Tawaha, & 
Oberlies, 2008; Al-Mahmoud, Alali, Tawaha, & Qasaymeh, 2006), the colchicinoids 
of Colchicum crocifolium Boiss. (Colchicaceae) were pursued. Alkaloids of the colchicinoid 
structural class are well known from this genus, particularly (−)-colchicine, and these compounds 
have been investigated extensively for both toxicological and potential medical properties. For 
example, (−)-colchicine is a drug of choice to relieve acute gout attack (Terkeltaub, 2003) and is 
used to combat a variety of pro-inflammatory disorders, such as familial Mediterranean fever 
(Drenth & van der Meer, 2001) and Behçet's disease (Sakane & Takeno, 2000). Colchicum 
crocifolium grows wildly in Jordan in clayey sandy desert, is a delicate, perennial herb, with 
corms covered by thick, dark-brown to reddish scales and is found flowering from March to 
April (Al-Eisawi, 1998). In preliminary studies where C. crocifolium was used as a model 
organism to demonstrate the feasibility and value of an LC-MS and LC-PDA system to 
dereplicate colchicinoids (Alali et al., 2008), 10 known alkaloids were dereplicated in addition to 
a new compound, which was proposed to be N,N-dimethyl-N-deacetyl-(−)-cornigerine (Alali et 
al., 2008). Those promising results stimulated our research team to conduct a full phytochemical 
characterisation of the active components in C. crocifolium, which to the best of our knowledge 
had not been studied previously. 
 
From extracts of the whole plant (leaves, stems, corms and seeds), five colchicinoids were 
isolated and characterised. One of these, N,N-dimethyl-N-deacetyl-(−)-cornigerine (5), is a new 
colchicinoid analogue, while the other four are known compounds that are new to the species: 
(−)-colchicine (1), (−)-demecolcine (2), (−)-N-methyl-(−)-demecolcine (3) and 3-demethyl-N-
methyl-(−)-demecolcine (4). The structures of all compounds were elucidated using a series of 
spectrometric and spectroscopic techniques. All compounds (1–5) were evaluated for their 
cytotoxicity against a human cancer cell panel. 
 




Optical rotation, IR and UV data were obtained on a Rudolph Research Autopol III polarimeter, 
a Nicolet Avatar 360 FT-IR, and a MultiSpec-1501, SHIMADZU® photodiode diode array 
spectrophotometer (Kyoto, Japan), respectively. All NMR experiments were performed in 
CDCl3 with TMS as an internal standard; 1H-, 13C-NMR, DEPT-135, gs-COSY and gs-HSQC 
NMR spectra were acquired on a Bruker 400 MHz NMR spectrometer (Industriestr., Fällanden, 
Switzerland), while a Varian Unity Inova-500 instrument with a 5 mm broad-band inverse probe 
with z-gradient (Varian Inc., Palo Alto, CA) was utilised for ROESY and gs-HMBC NMR 
spectra. Low-resolution ESIMS and APCIMS were determined on an Agilent® (Palo Alto, CA, 
USA) ion-trap LC/MS system; HRMS were acquired using an Applied Biosystems 
(Framingham, MA) TOF/TOF mass spectrometer, equipped with a Nd : YAG laser operating at 
355 nm and 200 Hz. This instrument was operated in the reflectron mode, and the matrix 
employed was 2,5-dihydroxybenzoic acid prepared at a concentration of 9 mg mL−1 in 70 : 30 (v 
: v) acetonitrile–0.1% trifluoroacetic acid. HPLC was performed on a Lachrom® MERCK-
HITACHI (Tokyo, Japan), equipped with quaternary gradient L-7150 pump, L-7455 diode-array 
detector, L-7200 auto-sampler and D-7000 interface. The preparative HPLC column was a 
Hibar® MERCK, pre-packed column RT 250-25, Lichrosorb® RP-18 (7 µm). PTLC was carried 
out on 20 × 20 cm plates with silica gel F254 (Merck KGaA, Germany). Column chromatography 
was carried out using silica gel 60 (0.06–0.2 mm; 70–230 mesh), and TLC utilised silica gel 60 
with gypsum and pigment addition for UV visualisation (both from Scharlau Chemie S.A., 
Barcelona, Spain). TLC spots were visualised by UV (VILBER LOURMAT, 4 W-254 nm tube) 
or by spraying the developed plates with 5% phosphomolybdic acid in EtOH. (−)-Colchicine 
standard was obtained from Fluka Chemie AG, Buchs. 
 
2.2. Plant material 
 
Corms, leaves, stems and seeds of C. crocifolium were collected during the seeding stage in 
April of 2005 and 2006 in the northeastern part of Jordan, from Ar-Rwaished (elevation 691 m, 
latitude 32°33′465″N, longitude 38°16′854″E), and identified by one of the authors (Khaled 
Tawaha). A voucher specimen (PHC# 110) was deposited in the Herbarium of the Faculty of 
Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. 
 
2.3. Extraction and isolation 
 
Air-dried plant raw material was ground to a fine powder using a laboratory mill, RetschMühle 
(RETSCH GmbH, Haan, Germany), and then it was passed through a 24 mesh sieve. Dried plant 
material (537.7 g) was extracted with MeOH in a Soxhlet apparatus for 3 h. The solvent was 
evaporated under reduced pressure to yield a MeOH-extract (148.1 g), which was fractionated 
based on the methods of Santavy et al. (1981) and Sutlupinar et al. (1988). Briefly, the MeOH-
extract was dissolved in 5% acetic acid, extracted with light petroleum (Fraction A) (12.0 g), 
after which the aqueous acid residue was re-extracted three times with diethyl ether (Fraction B) 
(1.2 g). The acidic aqueous residues were made alkaline (pH 9) with 10% NH4OH followed by 
triple extraction with CH2Cl2 (Fraction C) (1.9 g). All fractions were dried in vacuo. Fraction C 
(1.9 g) was subjected to chromatography over silica gel using a gradient of 100% hexane to 
100% CH2Cl2 to 2.4% MeOH in CH2Cl2, to yield 13 pools. Pure compounds were isolated via 
prep-HPLC from alkaloid-rich pools (3–10) using a gradient solvent system of CH3CN and 3% 
acetic acid in water (10 : 90 to 60 : 40 over 40 min) with a 10 mL min−1 flow rate, monitoring at 
245 nm, and injecting between 50 and 400 mg of material dissolved in 2 mL of MeOH and 
mobile phase in a 1 : 1 ratio. The purity of the isolated compounds was verified by TLC 
developed with either CHCl3 : MeOH [9 : 1] or CH2Cl2 : acetone : diethylamine [12 : 6 : 2]. 
 
2.3.1. N,N-Dimethyl-N-deacetyl-(−)-cornigerine (5) 
 
Yellowish powder (95.9 mg); UV (MeOH) λ max(log ε) 242 (4.64) nm; α D 23 −106 (c 0.0035, 
MeOH); IR ν max 3686, 3017 (base peak), 2436, 2396, 2362, 1557, 1520, 1474, 1419, 1217, 1029 
and 930 cm−1; for 1H (400 MHz, CDCl3) and 13C (125 MHz, CDCl3) NMR data, see Table 1; ESI 
MS (pos. ion mode) m/z 370.3 [M + H+], 338.1 [MH–MeOH+], 327.0 MH–N(Me) = CH2 +, 
299.1 [MH–N(Me) = CH2–CO+]; HR TOF/TOF MS m/z 370.16374 [M + H+] (Calcd for 
[C21H23NO5 + H]+, 370.16490). 
 
2.4. Human cancer cell panel 
 
The cytotoxicity measurements against the MCF-7 human breast carcinoma (Barbara A. 
Karmanos Cancer Center, Detroit, MI), NCI-H460 human large cell lung carcinoma (American 
Type Culture Collection, Manassas, VA) and SF-268 human astrocytoma (NCI Developmental 
Therapeutics Program, Frederick, MD) cell lines were performed as described previously 
(Alali, 2005). 
 
Table 1. 1H, 13C, DEPT-135 and HMBC NMR data (in CDCl3) for compound 5. 
Position δC DEPT δH, multiplicity (J in Hz) HMBC (H → C) 
 1 140.1 C     
 2 137.3 C     
 3 148.7 C     
 4 103.2 CH 6.43 s 1, 2, 3, 5, 12b 
 4a 134.0 C     
 5 30.3 CH2 2.21 m, 2.40 m 4, 4a, 6, 7, 12b 
 6 36.4 CH2 1.70 m, 2.19 m 4a, 5, 7, 7a, 12b 
 7 68.2 CH 2.68 dd (6, 6) 6, 7a, 8, 12, 12a 
 7a 152.3 C     
 8 133.5 CH 8.07 s 7, 7a, 12, 12a, 9, 10 
 9 180.0 C     
10 163.9 C     
11 111.6 CH 6.80 d (10.5) 9, 10, 12, 12a 
12 134.1 CH 7.17 d (10.5) 7a, 10, 12a, 12b 
12a 136.5 C     
12b 125.1 C     
O–CH2–O 101.2 CH2 5.99, 6.02 d (13) 2, 3 
1-OCH3 59.9 CH3 3.84 s 1 
10-OCH3 56.1 CH3 3.98 s 10 
N(CH3)2 43.5 (CH3)2 2.09 s   
 
3. Results, discussion and conclusions 
 
Air-dried ground plant material of C. crocifolium Boiss. (Colchicaceae) was processed into three 
fractions (A–C) according to the schemes of Santavy, Preininger, Simanek, and Potesilova 
(1981) and Sutlupinar et al. (1988). A high concentration of colchicinoids was noted in the TLC 
of fraction C by distinctive yellow spots after spraying with 5% phosphomolybdic acid in EtOH. 
Thus, fraction C was subjected to further purification using a series of chromatographic 
techniques: open columns, preparative TLC and semi-preparative HPLC. Five pure compounds, 
four known but new to the species, along with a new one, were isolated and their structures were 
elucidated using a suite of spectroscopic techniques, principally: 1D-NMR (1H and 13C), 2D-
NMR (COSY, ROESY, HMBC and HSQC), mass spectra analyses (low-resolution ESI-MS and 
high-resolution TOF/TOF MS) and by comparisons with data in the literature (Alali, 2005, 
2006a). These compounds were all of (−)-colchicine-type: (−)-colchicine (1) (23.6 mg, 0.004% 
w/w), (−)-demecolcine (2) (50.3 mg, 0.009% w/w), (−)-N-methyl-(−)-demecolcine (3) (12.6 mg, 
0.002% w/w), 3-demethyl-N-methyl-(−)-demecolcine (4) (6.02 mg, 0.001 w/w) and N,N-
dimethyl-N-deacetyl-(−)-cornigerine (5) (95.9 mg, 0.018% w/w) (Figure 1). The spectroscopic 
and spectrometric data of the four known compounds: (−)-colchicine (1) (Alali, 2005), (−)-
demecolcine (2) (Alali, 2005), (−)-N-methyl-(−)-demecolcine (3) (Alali, 2006a) and 3-demethyl-
N-methyl-(−)-demecolcine (4) (Alali, 2006a), were in full agreement with the literature. 
 
 
Figure 1. Chemical structures of (−)-colchicine (1), (−)-demecolcine (2), (−)-N-methyl-(−)-
demecolcine (3), 3-demethyl-N-methyl-(−)-demecolcine (4) and N,N-dimethyl-N-deacetyl-(−)-
cornigerine (5). 
 
Compound 5 (95.9 mg) was obtained as a yellowish powder. The HR TOF/TOF MS data 
(observed m/z 370.16374 for [M + H]+) revealed the molecular formula to be C21H23NO5. The 1H 
NMR spectrum (Table 1) showed signals assignable to five methine protons at δ H 6.43 (H-4), 
2.68 (H-7), 8.07 (H-8), 6.80 (H-11) and 7.17 (H-12); three pairs of methylene protons 2.21 (H-
5a), 2.40 (H-5b), 1.70 (H-6a), 2.19 (H-6b), and 5.99 and 6.02 for (O–CH2–O); and four sets of 
methyl protons 3.84 (1-OCH3), 3.98 (10-OCH3) and 2.09 (N(CH3)2). In the 13C and DEPT-135 
NMR spectra, signals were observed for: eight quaternary carbons at δ C 140.1 (C-1), 137.3 (C-
2), 148.7 (C-3), 134.0 (C-4a), 152.3 (C-7a), 163.9 (C-10), 136.5 (C-12a) and 125.1 (C-12b); four 
tertiary carbons at 59.9 (1-OCH3), 56.1 (10-OCH3) and 43.5 (N(CH3)2); three secondary carbons 
at 30.3 (C-5), 36.4 (C-6) and 101.2 (O–CH2–O); five primary carbons at 103.2 (C-4), 68.2 (C-7), 
133.5 (C-8), 111.6 (C-11) and 134.1 (C-12); and a ketone carbonyl carbon at 180.0 (C-9). The 
complete 1H, 13C, DEPT-135 and HMBC data sets are shown in Table 1. The 1D-NMR data 
revealed the presence of a methylenedioxy ring, which was characteristic of (−)-cornigerine-
related compounds (Alali, 2005). In particular, compound 5 differed from (−)-cornigerine by 
having an N,N-dimethyl group at C-7 instead of the N-acetyl moiety. A broad singlet at δ H8.07 
(H-8), an AB pattern at δ H 7.17 and 6.80 (d, J = 10.5 Hz; H-12 and H-11, respectively), and an 
upfield-shifted ketone carbonyl at δ C 180.0 (C-9) were characteristic for a tropolone C-ring 
(Alali, 2005), whose presence was confirmed by corresponding HMBC data (Table 1, Figure 2). 
One of the methoxy moieties (δ H 3.98) was placed at C-10 due to an HMBC correlation. The 
other methoxy group (δ H/δ C 3.84/59.9) was placed at C-1 due to an HMBC correlation, as is 
typical in colchicinoids (Figure 2) (Alali, 2005). The presence of the characteristic 
methylenedioxy ring (δ H/δ H/δ C 5.99/6.02/101.3) was confirmed by the HMBC correlations of 
its two protons with C-3 and C-2 (Figure 2), and by ROESY correlations with (H-4) and (1-
OCH3) (Figure 3). A broad peak at δ H/δ C 2.09/43.5 was assigned to the N,N-dimethyl residues; 
this unusual NMR pattern of the N,N-dimethyl at C-7 was observed previously by our research 
team in (−)-N-methyl-(−)-demecolcine and 3-demethyl-N-methyl-(−)-demecolcine 
(Alali, 2006a). The structure of 5 was thus established as N,N-dimethyl-N-deacetyl-(−)-
cornigerine, a new colchicine analogue. Figure 4 shows the fragmentation pattern of N,N-
dimethyl-N-deacetyl-(−)-cornigerine (5); this is the first attempt to interpret (+)-ESI-MS/MS 
fragments of colchicinoids. Based on the well-established biosynthetic pathway of colchicinoids 
(Herbert, 2001; Maier, 1997; McDonald et al., 1998; Nasreen, Rueffer, & Zenk, 1996), the 
stereochemistry at position C-7 was presumed to be S. 
 
Compounds 1–5 were tested for cytotoxicity against a human cancer cell panel, where 1 and 2 
were the most potent (Table 2). The new compound 5 exhibited an unusual activity profile; while 
it had modest activity against two of the cell lines (H460 and SF268), its growth inhibitory 









Figure 3. Key ROESY correlations for N,N-dimethyl-N-deacetyl-(−)-cornigerine (5). 
 
 
Figure 4. Mass fragmentation pattern of N,N-dimethyl-N-deacetyl-(−)-cornigerine (5). 
 
Table 2. Human cancer cell panel results for compounds 1–5. 
Compound MCF-7 H460 SF268 
1 0.062 0.032 0.025 
2 0.052 0.044 0.039 
3 0.151 0.165 0.354 
4 2.44 3.20 9.81 
5 0.515 1.00 1.77 
Camptothecina 0.309 0.024 0.043 
Note: Cytotoxicity results are expressed as IC50 values (µM; concentration to inhibit growth by 
50%) and are derived from single experiments using 12 data points, each run in triplicate. 
IC50 values were determined as the concentration required to reduce cellular staining with 
sulforhodamine B by 50% relative to untreated controls following 72 h of continuous exposure 
(Alali, 2005); the percent standard deviation for each IC50 determination averaged 11% of each 
respective mean value, with none exceeding 35%. 
aPositive control. 
 
In summary, via our preliminary studies, a 2 mg aliquot of C. crocifolium extract was analysed 
using an LC-MS and LC-PDA systems to dereplicate 10 known alkaloids; constituents from each 
of the four major structural groups of colchicinoids were identified readily using that system. 
Moreover, the presence of new compounds was also suggested, particularly one that was 
proposed to be N,N-dimethyl-N-deacetyl-(−)-cornigerine (Alali et al., 2008). Those findings 
stimulated the present investigation, which was aimed at isolating cytotoxic components in C. 
crocifolium, both to have a larger amount of material to verify the dereplication data 
spectroscopically and to evaluate the compounds against a human cancer cell panel. To the best 
of our knowledge, this represents the first phytochemical evaluation of C. crocifolium, a species 
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